Q-linea AB (SE:QLINEA)
:QLINEA
Want to see SE:QLINEA full AI Analyst Report?
QLINEA Stock Chart & Stats
kr29.00
>-kr0.01(-3.85%)
At close: 4:00 PM EST
kr29.00
>-kr0.01(-3.85%)
Day’s Range― - ―
52-Week Rangekr16.70 - kr74.06
Previous CloseN/A
Volume6.05M
Average Volume (3M)13.43K
Market Cap
kr314.69M
Enterprise Value-kr130.18M
Total Cash (Recent Filing)kr258.11M
Total Debt (Recent Filing)kr7.71M
Price to Earnings (P/E)―
Beta2.52
Next Earnings
Jul 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding18,949,081
10 Day Avg. Volume10,725
30 Day Avg. Volume13,430
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.49
Price to Sales (P/S)14.97
P/FCF Ratio-0.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.51
Revenue Forecast (FY)kr76.80M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelQ-linea’s razor-and-blades commercial design creates durable recurring revenue as placed instruments drive ongoing consumables and reagent sales. Over time, a growing installed base can generate predictable high-frequency revenue and margin leverage if utilization rises, supporting long-term commercial scalability.
Clinical Platform Focus (sepsis & AST)The company’s automated platform targets sepsis and AST—areas of persistent clinical need where faster diagnostics materially affect outcomes. Structural healthcare priorities (antimicrobial stewardship, rapid care pathways) support sustained demand for reliable, rapid instruments and tests in hospitals and labs over multiple years.
Low Current LeverageModest reported debt and very low debt-to-equity provide financial flexibility and lower near-term default risk. This balance-sheet conservatism helps the company weather continued cash burn while pursuing placements and R&D, delaying the urgency of debt refinancing until commercial traction improves.
Bears Say
Persistent Cash BurnConsistently large negative operating and free cash flows indicate the business is not self-funding and will require external financing to continue operations and commercial expansion. Repeated funding rounds can dilute shareholders, constrain strategic choices, and increase execution risk over the medium term.
Negative Gross Profit And Large LossesNegative gross margins and persistent operating losses point to fundamental product economics problems—pricing, cost of goods, or low utilization of instruments. Without sustained margin improvement or pricing power, scaling sales will deepen losses and impede the path to sustainable profitability.
Volatile Revenue & Equity InstabilityErratic top-line performance and prior negative equity reflect uneven commercialization and funding volatility. Such instability undermines partner confidence, complicates long-term planning, and raises the likelihood of future capital raises or restructurings if revenue momentum is not consistently sustained.
Q-linea AB News
QLINEA FAQ
What was Q-linea AB’s price range in the past 12 months?
Q-linea AB lowest stock price was kr16.70 and its highest was kr74.06 in the past 12 months.
What is Q-linea AB’s market cap?
Q-linea AB’s market cap is kr314.69M.
When is Q-linea AB’s upcoming earnings report date?
Q-linea AB’s upcoming earnings report date is Jul 09, 2026 which is in 68 days.
How were Q-linea AB’s earnings last quarter?
Currently, no data Available
Is Q-linea AB overvalued?
According to Wall Street analysts Q-linea AB’s price is currently Overvalued.
Does Q-linea AB pay dividends?
Q-linea AB does not currently pay dividends.
What is Q-linea AB’s EPS estimate?
Q-linea AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Q-linea AB have?
Q-linea AB has 18,949,081 shares outstanding.
What happened to Q-linea AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Q-linea AB?
Currently, no hedge funds are holding shares in SE:QLINEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Q-linea AB
Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in Sweden. It offers inventive systems for in vitro diagnostics systems for infectious diseases. The company's lead product candidate is ASTar, an antibiotic susceptibility testing system used for positive blood cultures. It develops and delivers solutions for healthcare providers. Q-linea AB (publ) was incorporated in 2008 and is headquartered in Uppsala, Sweden.
Technical Analysis
Vicore Pharma Holding AB
―
Isofol Medical AB
―
Biovica International AB Class B
―
Doxa AB
―
Guard Therapeutics International AB
―